Ascendiant analyst Edward Woo raised the firm’s price target on RenovoRx (RNXT) to $11.50 from $11 and keeps a Buy rating on the shares. The company reported Q1 results with strong revenue growth, the analyst tells investors in a research note. The firm says the RenovoCath commercialization and positive clinical data in Q3 will be “strong catalysts” for the stock.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook
- RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating
- RenovoRx Earnings Call: Positive Outlook Amid Growth
- RenovoRx Reports Promising Q1 2025 Financial Results
- RenovoRx Reports Strong Q1 2025 Financial Results